FAAS yields 2469.14% · JNJ yields 2.14%● Live data
📍 FAAS pulled ahead of the other in Year 1
Combined, FAAS + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FAAS + JNJ for your $10,000?
DigiAsia Corp. develops an AI embedded finance platform in Southeast Asia. It offers B2B fintech platform for bill payments, supply chain payments, and branchless banking solutions for merchants, partners, and customers; digital wallets; QRIS Payment as a Service; Cash Management system for ERP system that allows users to create a closed-loop cash management system; Digital Product & Billers, which allows users to purchase digital products or pay bills to multiple issuers or billers; and Remittance Product that enables users to transfer funds from their application cash-to-cash, cash-to-account, account-to-cash, and account-to-account. The company also provides B2B Loan product for micro, small, and medium enterprises; Gold saving products; Virtual Card Number to generate a digital invoice for customers to accept payment over internet transactions; Buy Now Pay Later; e-KYC module to Onboard new customers securely in compliance with regulation; Cash in & Cash Out points; KasPro Bank for Banks and FSI to utilize their networks of retail outlets onboarded as licensed digital banking agents to offer cash-in & cash-out points to serve micro small, and medium enterprises. DigiAsia Corp. is headquartered in Jakarta, Indonesia.
Full FAAS Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.